Risk of Venous Thromboembolism in First-Degree Relatives of Women With or Without Venous Thromboembolism During Hormonal Exposure

What this Trial Is About

Young women face an increased risk of venous thromboembolism (VTE) when exposed to hormones such as estrogen-containing pills or during pregnancy. This research compares the occurrence of VTE in first-degree relatives of women who had VTE during hormonal exposure with those whose relatives did not experience VTE under similar hormonal conditions. The study aims to better understand the influence of family history and inherited thrombophilia on VTE risk in this population. The study is a cross-sectional, case-control design involving two groups: first-degree relatives of women who had a VTE event related to hormonal exposure and relatives of women with similar hormonal exposure but no VTE. Participants in both groups complete questionnaires and provide blood samples; some may also undergo an echo-doppler exam. The research investigates the presence of VTE in these relatives and evaluates genetic factors like factor V Leiden and the prothrombin 20210A gene variant. Participants provide consent and undergo assessments including medical history questionnaires, blood tests, and possible imaging to detect previous VTE events. Researchers will evaluate the prevalence of symptomatic VTE in first-degree relatives and analyze associated hereditary factors. The primary outcome focuses on whether relatives have had venous thromboembolism, with data collected promptly on enrollment. The study duration and follow-up are based on initial assessments and data analysis periods.

Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure